Immunotherapy for lung cancer before surgery

SPRING 01: Exploring the combination of avelumab, axitinib and palbociclib in patients with advanced metastatic NSCLC

CDK4/6 inhibitors in hormone receptor-positive, HER2-negative metastatic breast cancer

Gene expression in primary non-small cell lung cancer as a predictor of brain metastases

Integration of DNA and RNA investigations in clinical trials: A laboratory challenge

Implementing national cancer control plans

The potential of PARP inhibitors in new cancer groups and in combination with other treatments

Anti-tumour activity of TAK-788 in NSCLC patients with EGFR exon 20 insertions

A phase II study of bemcentinib with pembrolizumab in patients with advanced NSCLC

Expanding clinical trial eligibility criteria: Risks and solutions

Pembrolizumab increases long-term survival in patients with advanced NSCLC

Carfilzomib and irinotecan in relapsed small cell lung cancer